{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044224","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.131874+00:00","generated_at":"2026-06-07T15:39:09.008991+00:00","sec_items":["2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"AgeX draws $500K under secured note with Juvenescence, due Feb 14, 2024","bullets":["Drew $500,000 from existing secured convertible promissory note with Juvenescence Limited.","Repayment date set at February 14, 2024.","Note terms previously summarized in Form 10-Q filed Nov 14, 2023.","Obligation is secured and convertible; additional terms not detailed in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044224","json":"https://secwatch.observer/filing/0001493152-23-044224.json","markdown":"https://secwatch.observer/filing/0001493152-23-044224.md","text":"https://secwatch.observer/filing/0001493152-23-044224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223044224/0001493152-23-044224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223044224/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:39:09.008991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"039d47649d745a0c4840ef4a1d60213e8d5ab9ab","claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On December 5, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”). The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223044224/0001493152-23-044224-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}